Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Novel approaches in the treatment of lupus nephritis
Autore:
Illei, GG; Czirjak, L;
Indirizzi:
NIAMSD, Off Clin Director, NIH, Bethesda, MD 20892 USA NIAMSD Bethesda MDUSA 20892 f Clin Director, NIH, Bethesda, MD 20892 USA Univ Pecs, Clin Immunol Unit, Nephrol Ctr, Pecs, Hungary Univ Pecs Pecs Hungary s, Clin Immunol Unit, Nephrol Ctr, Pecs, Hungary Univ Pecs, Clin Immunol Unit, Dept Internal Med 2, Pecs, Hungary Univ Pecs Pecs Hungary Immunol Unit, Dept Internal Med 2, Pecs, Hungary
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 6, volume: 10, anno: 2001,
pagine: 1117 - 1130
SICI:
1354-3784(200106)10:6<1117:NAITTO>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
INTRAVENOUS IMMUNOGLOBULIN TREATMENT; MYCOPHENOLATE-MOFETIL THERAPY; ALLEVIATES DISEASE SEVERITY; VARIABLE REGION GENES; CONTROLLED TRIAL; AUTOIMMUNE-DISEASE; MURINE LUPUS; PULSE CYCLOPHOSPHAMIDE; CD40 LIGAND; B-CELL;
Keywords:
biological products; clinical trials; lupus nephritis; mycophenolate mofetil; systemic lupus erythematosus; therapy;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
112
Recensione:
Indirizzi per estratti:
Indirizzo: Illei, GG NIAMSD, Off Clin Director, NIH, 9000 Rockville Pike,Bldg 10,Rm 9S205, Bethesda, MD 20892 USA NIAMSD 9000 Rockville Pike,Bldg 10,Rm 9S205 Bethesda MD USA 20892
Citazione:
G.G. Illei e L. Czirjak, "Novel approaches in the treatment of lupus nephritis", EXPERT OP I, 10(6), 2001, pp. 1117-1130

Abstract

In systemic lupus erythematosus hyperactive helper T-cells drive polyclonal B-cell activation and secretion of pathogenic auto-antibodies. The autoantibodies form immune complexes with their respective auto-antigens, which in turn deposit in sites such as the kidney and initiate a destructive inflammatory reaction. Lupus nephritis can be managed successfully in the majority of cases; however, the most widely used immunosuppressive therapies, notably corticosteroids and cyclophosphamide are non-specific and are associated with substantial toxicities. Novel treatments for lupus nephritis have to be at least as effective and less toxic than existing therapies. The ultimate aim is to develop treatments that target specific steps in the diseaseprocess. Novel therapeutic strategies in the short-term more likely will focus on refining regimens of drugs that are already in use (mycophenolate mofetil, adenosine analogues) and combinations of existing chemotherapeutic agents, as well as attempts to achieve immunological reconstitution using immunoablative chemotherapy with or without haematopoietic stem cell rescue. Several new agents targeting specific steps in the pathogenesis of lupus are in various phases of clinical development. Interrupting the interactionsbetween T-lymphocytes and other cells by blocking co-stimulatory molecules, such as CD40 ligand or CTLA4-Ig, may interfere with the early steps of pathogenesis. Blocking IL-10 may decrease auto-antibody production and help normalise T-cell function. Treating patients with DNase or interfering with the complement cascade by blocking C5, or neutralising pathogenic antibodies by administering specific binding peptides or inducing specific anti-idiotype antibodies may prevent immune complex formation and/or deposition.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 10:15:13